
Kopran (KOPRAN) | Stock Overview & Key Data
Kopran Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: ₹370.45 on December 27, 2021
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Financial Highlights
Profitability
Returns and Earnings
Growth
Dividend Information
Peer Performance Comparison
Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
---|---|---|---|---|---|---|---|---|---|
Kopran KOPRAN | 9.18B Small-cap | 5.10% | 5.59% | 0.38% | -6.95% | -14.17% | -41.76% | 11.14% | 100.38% |
GlaxoSmithKline GLAXO | 466.84B Large-cap | 2.57% | -1.29% | -16.99% | -4.05% | 22.80% | 0.26% | 96.82% | 83.37% |
Pfizer PFIZER | 240.16B Large-cap | 5.91% | 0.94% | -9.69% | 28.32% | -1.60% | -7.01% | 17.65% | 3.99% |
Senores SENORES | 32.95B Small-cap | -4.06% | -1.93% | 18.10% | 22.01% | 20.44% | 20.06% | 20.06% | 20.06% |
Sms Pharmaceuticals SMSPHARMA | 23.10B Small-cap | 6.82% | 14.97% | 11.46% | 17.91% | 4.74% | -26.16% | 197.55% | 193.49% |
TTK Healthcare TTKHLTCARE | 16.28B Small-cap | -0.35% | -2.52% | -15.30% | -12.67% | -18.14% | -28.60% | 21.10% | 159.64% |
Ownership & Short Interest
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is KOPRAN's 52-week high and low?
- In the last 52 weeks, Kopran reached a high of ₹334.35 (on October 3, 2024) and a low of ₹154.06 (on August 28, 2025).
- What is the market cap and P/E ratio for KOPRAN?
- Curious about Kopran's size and valuation? Its market capitalization stands at 9.18B. When it comes to valuation, the P/E ratio (trailing twelve months) is 24.44, and the forward P/E (looking ahead) is 31.16.
- Does KOPRAN pay dividends? If so, what's the yield?
- Yes, Kopran is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 1.74%, and the company has paid an average of ₹3.00 per share annually over the past 3 years.
- Who are Kopran's main competitors or similar companies to consider before investing?
When looking at Kopran, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return GlaxoSmithKline
GLAXO466.84B Healthcare Drug Manufacturers - General 0.26% 96.82% Pfizer
PFIZER240.16B Healthcare Drug Manufacturers - General -7.01% 17.65% Senores
SENORES32.95B Healthcare Drug Manufacturers - General 20.06% 20.06% Sms Pharmaceuticals
SMSPHARMA23.10B Healthcare Drug Manufacturers - General -26.16% 197.55% TTK Healthcare
TTKHLTCARE16.28B Healthcare Drug Manufacturers - General -28.60% 21.10% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Kopran Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Kopran's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 7.44%, the Debt to Equity ratio from the most recent quarter is 28.51, and its Gross Profit Margin stands at 36.84%.
- What is the recent revenue and earnings growth for KOPRAN?
- Looking at Kopran's growth, its revenue over the trailing twelve months (TTM) was INR6B. Compared to the same quarter last year (YoY), quarterly revenue grew by -3.00%, and quarterly earnings saw a YoY growth of -32.90%.
- How much of KOPRAN stock is held by insiders and institutions?
- Wondering who owns Kopran stock? Company insiders (like executives and directors) hold about 48.38% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.38%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.